# GlaxoSmithKline: Phase 1 study closed enrollment, 122 enrolled (Pneumonia, Bacterial)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years |
| NCT ID | NCT07428759 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Pneumonia, Bacterial |
| Intervention types | biological, combination product |
| Target enrollment | 122 |
| Site countries | Australia |
| Posted | 2026-02-24 |
| Planned start | 2026-03-10 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-27 |
| Last update posted | 2026-10-27 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- 122 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07428759). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.